Program
Phenobarbital
Also written as “Phenobarbital Sodium Injection” and “Sezaby”.
Its studies are mostly in Seizures · Epilepsy, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hikma Pharmaceuticals | 10 open or running | phase 3since Jan 20, 2011 | Jan 20, 2011 | none ahead |
| NEMA Research | 10 open or running | phase 3since Mar 23, 2020 | Mar 23, 2020 | none ahead |
| PharPoint Research | 10 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| Sun Pharmaceutical Industries | 11 open or running | phase 4since Oct 13, 2026 | Oct 13, 2026 | Mar 2028phase 4 · NCT07923734 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2011First study: phase 3 study in EpilepsyNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT01284556 · 314 enrolled · United States, Puerto Rico
- Jul 17, 2018PharPoint Research's first study: phase 3 study in Neonatal SeizureNew to PharPoint ResearchPharPoint Research · NCT03602118
- Mar 23, 2020NEMA Research's first study: phase 3 study in Epilepsy, Benign NeonatalNew to NEMA ResearchNEMA Research · NCT04320940 · 4 enrolled · United States, Jordan
- Oct 13, 2026Sun Pharmaceutical Industries's first study: phase 4 study in Neonatal SeizureNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07923734 · 45 planned · United States
Ahead
- Mar 2028Primary completion: phase 4 study in Neonatal SeizureSun Pharmaceutical Industries · NCT07923734
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07923734Neonatal Seizure · United States | 4 | Not yet recruiting | Sun Pharmaceutical Industries | Mar 2028 | 45 |
| NCT04320940Epilepsy, Benign Neonatal · United States, Jordan | 3 | Terminated | NEMA Research | Feb 1, 2023 | 4 |
| NCT03602118Neonatal Seizure | 3 | Withdrawn | PharPoint Research | May 1, 2021 | 0 |
| NCT01284556Epilepsy · United States, Puerto Rico | 3 | Completed | Hikma Pharmaceuticals | Jan 2013 | 314 |
How it is read
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.